Drug Profile
Research programme: type 2 diabetes therapeutics - Boehringer/Assertio Therapeutics
Latest Information Update: 20 Aug 2018
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Depomed
- Developer Assertio Therapeutics; Boehringer Ingelheim
- Class
- Mechanism of Action Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany (Parenteral)
- 29 Mar 2012 Preclinical development is ongoing in Germany